US20210008035A1 - Liquid formulations of bendamustine - Google Patents
Liquid formulations of bendamustine Download PDFInfo
- Publication number
- US20210008035A1 US20210008035A1 US16/835,562 US202016835562A US2021008035A1 US 20210008035 A1 US20210008035 A1 US 20210008035A1 US 202016835562 A US202016835562 A US 202016835562A US 2021008035 A1 US2021008035 A1 US 2021008035A1
- Authority
- US
- United States
- Prior art keywords
- bendamustine
- formulations
- days
- formulation
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- YTKUWDBFDASYHO-UHFFFAOYSA-N bendamustine Chemical compound ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 YTKUWDBFDASYHO-UHFFFAOYSA-N 0.000 title claims abstract description 71
- 229960002707 bendamustine Drugs 0.000 title claims abstract description 66
- 239000012669 liquid formulation Substances 0.000 title claims abstract description 14
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 claims description 14
- 239000003880 polar aprotic solvent Substances 0.000 abstract description 11
- 150000003839 salts Chemical class 0.000 abstract description 11
- 239000000203 mixture Substances 0.000 description 73
- 238000009472 formulation Methods 0.000 description 64
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 62
- ZHSKUOZOLHMKEA-UHFFFAOYSA-N 4-[5-[bis(2-chloroethyl)amino]-1-methylbenzimidazol-2-yl]butanoic acid;hydron;chloride Chemical compound Cl.ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 ZHSKUOZOLHMKEA-UHFFFAOYSA-N 0.000 description 29
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 21
- 238000004458 analytical method Methods 0.000 description 19
- 229960001215 bendamustine hydrochloride Drugs 0.000 description 18
- 238000004128 high performance liquid chromatography Methods 0.000 description 16
- 239000003586 protic polar solvent Substances 0.000 description 16
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 15
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 15
- 239000000243 solution Substances 0.000 description 15
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- 238000000034 method Methods 0.000 description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 8
- 238000001990 intravenous administration Methods 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- 229940066958 treanda Drugs 0.000 description 8
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 238000001802 infusion Methods 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 6
- -1 polybutylene Polymers 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 5
- 229960003966 nicotinamide Drugs 0.000 description 5
- 235000005152 nicotinamide Nutrition 0.000 description 5
- 239000011570 nicotinamide Substances 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 241000282567 Macaca fascicularis Species 0.000 description 4
- 229940034982 antineoplastic agent Drugs 0.000 description 4
- 239000002246 antineoplastic agent Substances 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 229920000136 polysorbate Polymers 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- RUOJZAUFBMNUDX-UHFFFAOYSA-N propylene carbonate Chemical compound CC1COC(=O)O1 RUOJZAUFBMNUDX-UHFFFAOYSA-N 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 229920000858 Cyclodextrin Polymers 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 235000019253 formic acid Nutrition 0.000 description 3
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000008176 lyophilized powder Substances 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- CYSGHNMQYZDMIA-UHFFFAOYSA-N 1,3-Dimethyl-2-imidazolidinon Chemical compound CN1CCN(C)C1=O CYSGHNMQYZDMIA-UHFFFAOYSA-N 0.000 description 2
- GPYWLSZJZNELNN-UHFFFAOYSA-N 4-[5-[bis(2-chloroethyl)amino]-1-methylbenzimidazol-2-yl]-4-hydroxybutanoic acid Chemical compound ClCCN(CCCl)C1=CC=C2N(C)C(C(O)CCC(O)=O)=NC2=C1 GPYWLSZJZNELNN-UHFFFAOYSA-N 0.000 description 2
- XKJMBINCVNINCA-UHFFFAOYSA-N Alfalone Chemical compound CON(C)C(=O)NC1=CC=C(Cl)C(Cl)=C1 XKJMBINCVNINCA-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 208000017604 Hodgkin disease Diseases 0.000 description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 208000034578 Multiple myelomas Diseases 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 2
- 239000000010 aprotic solvent Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 2
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 2
- 229940097362 cyclodextrins Drugs 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 229960005160 dimyristoylphosphatidylglycerol Drugs 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- BPHQZTVXXXJVHI-AJQTZOPKSA-N ditetradecanoyl phosphatidylglycerol Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@@H](O)CO)OC(=O)CCCCCCCCCCCCC BPHQZTVXXXJVHI-AJQTZOPKSA-N 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000013618 particulate matter Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 229940068965 polysorbates Drugs 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 239000012047 saturated solution Substances 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- BPZIKXXNXMYQPN-UHFFFAOYSA-N 4-[6-[bis(2-chloroethyl)amino]-1h-benzimidazol-2-yl]butanoic acid Chemical compound C1=C(N(CCCl)CCCl)C=C2NC(CCCC(=O)O)=NC2=C1 BPZIKXXNXMYQPN-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- OONRFSBQQJQYPV-UHFFFAOYSA-N C.CC(=O)CCCC1=NC2=CC(N(CCO)CCOC(=O)CCCC3=NC4=CC(N(CCO)CCCl)=CC=C4N3C)=CC=C2N1C Chemical compound C.CC(=O)CCCC1=NC2=CC(N(CCO)CCOC(=O)CCCC3=NC4=CC(N(CCO)CCCl)=CC=C4N3C)=CC=C2N1C OONRFSBQQJQYPV-UHFFFAOYSA-N 0.000 description 1
- FLEJWNISAYNFNT-UHFFFAOYSA-N CC(CO)OC(=O)CCCC1=NC2=CC(N(CCCl)CCCl)=CC=C2N1C.CC(O)COC(=O)CCCC1=NC2=CC(N(CCCl)CCCl)=CC=C2N1C Chemical compound CC(CO)OC(=O)CCCC1=NC2=CC(N(CCCl)CCCl)=CC=C2N1C.CC(O)COC(=O)CCCC1=NC2=CC(N(CCCl)CCCl)=CC=C2N1C FLEJWNISAYNFNT-UHFFFAOYSA-N 0.000 description 1
- PFTRYOMJJKBZKV-UHFFFAOYSA-N CN1C2=CC=C(N(CCO)CCCl)C=C2N=C1CCCC(=O)O Chemical compound CN1C2=CC=C(N(CCO)CCCl)C=C2N=C1CCCC(=O)O PFTRYOMJJKBZKV-UHFFFAOYSA-N 0.000 description 1
- GFGINMBRVNTAEV-UHFFFAOYSA-N CN1C2=CC=C(N(CCO)CCCl)C=C2N=C1CCCC(=O)O.P Chemical compound CN1C2=CC=C(N(CCO)CCCl)C=C2N=C1CCCC(=O)O.P GFGINMBRVNTAEV-UHFFFAOYSA-N 0.000 description 1
- UMRNCYQXTUODGC-UHFFFAOYSA-N CN1C2=CC=C(NCCCl)C=C2N=C1CCCC(=O)O Chemical compound CN1C2=CC=C(NCCCl)C=C2N=C1CCCC(=O)O UMRNCYQXTUODGC-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 229920002556 Polyethylene Glycol 300 Polymers 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 125000005233 alkylalcohol group Chemical group 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical group 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000008139 complexing agent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229960003624 creatine Drugs 0.000 description 1
- 239000006046 creatine Substances 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 239000008380 degradant Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000003073 embolic effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000003191 femoral vein Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical class ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
- 229960004961 mechlorethamine Drugs 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000012038 nucleophile Substances 0.000 description 1
- 230000000269 nucleophilic effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 229920001748 polybutylene Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 150000003138 primary alcohols Chemical class 0.000 description 1
- 150000003140 primary amides Chemical class 0.000 description 1
- 235000010388 propyl gallate Nutrition 0.000 description 1
- 239000000473 propyl gallate Substances 0.000 description 1
- 229940075579 propyl gallate Drugs 0.000 description 1
- 230000006920 protein precipitation Effects 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 210000003752 saphenous vein Anatomy 0.000 description 1
- 239000008354 sodium chloride injection Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000008227 sterile water for injection Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 231100000048 toxicity data Toxicity 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Definitions
- the present invention relates to liquid formulations of bendamustine, and the pharmaceutical salts thereof.
- bendamustine In light of its instability in aqueous solution, bendamustine is currently supplied as a lyophilized powder for injection. Just prior to its infusion, the medical practitioner reconstitutes the powder with Sterile Water for Injection. Reconstitution should yield a clear, colorless to pale yellow solution and the powder should completely dissolve in about 5 minutes. If particulate matter is observed, the reconstituted product should not be used and should be discarded. The reconstituted product is then transferred to a 0.9% Sodium Chloride Injection infusion bag within 30 minutes of reconstitution. This admixture should be a clear and colorless to slightly yellow solution. If the admixture comprises particulate matter or is discolored, it should be discarded and a fresh sample prepared.
- the present invention is directed to liquid pharmaceutical formulations comprising bendamustine, or a pharmaceutically acceptable salt or prodrug thereof, and a polar aprotic solvent.
- Certain preferred embodiments include liquid pharmaceutical formulations comprising bendamustine, or a pharmaceutically acceptable salt or prodrug thereof, a polar aprotic solvent, and a non-aqueous polar protic solvent.
- FIG. 1 is a graph of a stability analysis of bendamustine in various solvents at 25° C.
- FIG. 2 is a graph of a stability analysis of bendamustine in various solvents at 5° C.
- FIG. 3 is a graph of bendamustine purity, over time, in 99% propylene glycol, at 5° C. and at 25° C.
- pharmaceutically acceptable liquid formulations of bendamustine, and the pharmaceutically acceptable salts thereof, in particular the hydrochloride salt can be prepared by combining bendamustine, or the pharmaceutically acceptable salt thereof, with a polar aprotic solvent or mixture of polar aprotic solvents.
- Polar, aprotic solvents are known in the art and include, for example, 1-methyl-2-pyrrolidone, 1,3-dimethyl-2-imidazolidinone, dimethylacetamide, dimethyl sulfoxide, acetone, tetrahydrofuran, 1,4-dioxane, acetonitrile, dimethyl formamide, propylene carbonate.
- Organic solvents for pharmaceutical parenterals and embolic liquids include dimethylacetamide, dimethyl sulfoxide, and mixtures thereof.
- polar, aprotic solvents are sufficiently non-nucleophilic towards bendamustine such that polar aprotic solvent-bendamustine adducts do not form over the course of typical commercial storage conditions.
- Typical commercial storage conditions include time periods of, for example, about 30 days, about 90 days, about 180 days, and about 365 days (about 1 month, about 3 months, about 6 months, and about 1 year).
- Typical commercial storage conditions also include temperatures of about 23° C. (ambient room temperature) and refrigerated temperatures below ambient room temperature, for example, about 5° C.
- the liquid formulations of the present invention are stored at refrigerated temperatures.
- nonaqueous polar protic solvents include alkyl alcohols, for example, ethanol, ethylene glycol, propylene glycol, butylene glycol, glycerin, polysorbates, for example TWEEN 20, TWEEN 40, and TWEEN 80, and cyclodextrins (such as hydroxypropyl-(3-cyclodextrin), polyalkylene glycols, such as polyethylene glycol, polypropylene glycol, and polybutylene glycol, and primary amides such as niacinamide.
- alkyl alcohols for example, ethanol, ethylene glycol, propylene glycol, butylene glycol, glycerin
- polysorbates for example TWEEN 20, TWEEN 40, and TWEEN 80
- cyclodextrins such as hydroxypropyl-(3-cyclodextrin
- polyalkylene glycols such as polyethylene glycol, polypropylene glycol, and polybutylene glycol
- Such formulations will typically comprise 90% or less, by volume of the formulation, of the nonaqueous polar protic solvent. In other preferred embodiments, formulations will comprise between about 20% and about 85%, by volume of the formulation, of the nonaqueous polar protic solvent. In still other embodiments, formulations will comprise between about 30% and about 70%, by volume of the formulation, of the nonaqueous polar protic solvent. In most preferred embodiments, formulations will comprise about 80%, about 67% or about 34%, by volume of the formulation, of the nonaqueous polar protic solvent.
- formulations of the present invention will comprise 10 moles per liter, or less, of the nonaqueous polar protic solvent.
- formulations of the present invention will comprise between about 4 moles per liter to about 9.5 moles per liter, of the nonaqueous polar protic solvent.
- formulations will comprise about 9.1 moles per liter of the nonaqueous polar protic solvent.
- formulations will comprise about 4.6 moles per liter, of the nonaqueous polar protic solvent.
- nonaqueous polar protic solvents are of sufficient nucleophilicity to form potentially undesirable polar protic solvent-bendamustine adducts, such adducts will not form during typical commercial storage if the concentration of the polar protic solvent is kept within the scope of the present invention.
- Liquid formulations of the present invention are stable over the course of a typical commercial storage period.
- “stable” is defined as no more than about a 10% loss of bendamustine under typical commercial storage conditions.
- formulations of the present inventions will have no more than about a 10% loss of bendamustine, more preferably, no more than about a 5% loss of bendamustine, under typical commercial storage conditions.
- Bendamustine converts to non-bendamustine products (i.e., “degrades”) upon exposure to certain nucleophiles, for example, water and alkyene glycols such as propylene glycol. Exposure of bendamustine to water can produce “HP1,” which is undesirable.
- BM1 dimer Another undesirable compound that bendamustine can convert to over time is “BM1 dimer.”
- DCE Still another undesirable compound that bendamustine can convert to over time is “DCE.”
- esters of bendamustine can form, e.g., PG-1 and PG-2.
- analysis of formulations of the present invention will exhibit 1.50% or less of DCE, as determined by HPLC analysis, after about 1 year (about 365 days) at about 5° C. More preferably, the formulations will exhibit 1.0% or less of DCE, as determined by HPLC analysis, after about 1 year (about 365 days) at about 5° C. Even more preferably, the formulations will exhibit 0.5% or less of DCE, as determined by HPLC analysis, after about 1 year (about 365 days) at about 5° C. Most preferably, the formulations will exhibit about 0.1% or less of DCE, as determined by HPLC analysis, after about 1 year (about 365 days) at about 5° C.
- analysis of the formulations will exhibit about 0.4% or less of HP1, as determined by HPLC analysis, after about 1 year (about 365 days) at about 5° C.
- the formulations will exhibit about 0.10% or less of HP1, as determined by HPLC analysis, after about 1 year (about 365 days) at about 5° C.
- analysis of the formulations will exhibit about 0.70% or less of BM1 dimer, as determined by HPLC analysis, after about 1 year (about 365 days) at about 5° C.
- the formulations will exhibit about 0.30% or less of dimer, as determined by HPLC analysis, after about 1 year (about 365 days) at about 5° C.
- the formulations will exhibit about 0.10% or less of BM1 dimer, as determined by HPLC analysis, after about 1 year (about 365 days) at about 5° C.
- alkylene glycol as the nonaqueous polar protic solvent
- analysis of those formulations will exhibit 1.5% or less of alkylene glycol esters of bendamustine, as determined by HPLC analysis, after about 1 year (about 365 days) at about 5° C.
- analysis of those formulations will exhibit 1.5% or less of propylene glycol esters PG-1 and PG-2, as determined by HPLC analysis, after about 1 year (about 365 days) at about 5° C.
- Analysis of the liquid formulations of the present invention can be performed using techniques known in the art, including, for example, HPLC, gas chromatography, and NMR. After exposure to typical commercial storage conditions, analysis of the formulations of the present invention will indicate that the formulation contains no less than about 90% of the amount of bendamustine present prior to exposure to the storage conditions. Preferably, analysis will indicate that the formulation contains no less than about 95% of the amount of bendamustine present prior to exposure to the storage conditions.
- analysis of the formulations of the present invention will indicate that the formulation contains no less than about 90% of the amount of bendamustine present prior to exposure to storage conditions that include temperatures of about 5° C. and time periods of about 30 days (about 1 month) to about 365 days (about 1 year).
- analysis of the formulations of the present invention will indicate that the formulation contains no less than about 90% of the amount of bendamustine present prior to exposure to storage conditions that include temperatures of about 5° C. and time periods of about 30 days (about 1 month), about 90 days (about 3 months), and about 180 days (about 6 months).
- analysis will indicate that the formulation contains no less than about 95% of the amount of bendamustine present prior to exposure to storage conditions that include temperatures of about 5° C. and time periods of about 30 days (about 1 month) to about 365 days (about 1 year). More preferably, analysis will indicate that the formulation contains no less than about 95% of the amount of bendamustine present prior to exposure to storage conditions that include temperatures of about 5° C. and time periods of about 30 days (about 1 month), about 90 days (about 3 months), and about 180 days (about 6 months).
- Formulations of the present invention can comprise pharmaceutically useful concentrations of bendamustine, or a pharmaceutically acceptable salt thereof.
- Useful concentrations include concentrations ranging from about 5 mg/mL to about 200 mg/mL.
- the concentration of bendamustine, or a pharmaceutically acceptable salt thereof ranges from about 5 mg/mL to about 120 mg/mL.
- Preferred concentrations include about 5 mg/mL, about 10 mg/mL, about 20 mg/mL, about 30 mg/mL, about 40 mg/mL, about 50 mg/mL, about 60 mg/mL, about 100 mg/mL and about 200 mg/mL of bendamustine, or a pharmaceutically acceptable salt thereof.
- Greater than 200 mg/ml of bendamustine, or a pharmaceutically acceptable salt thereof, for example, greater than about 300 mg/mL are also within the scope of the present invention, as are saturated solutions of bendamustine, or a pharmaceutically acceptable salt thereof.
- formulations of the present invention may further comprise other pharmaceutically acceptable excipients.
- antioxidants e.g., tocopherol (Vitamin E), ascorbic acid, methyl paraben, butylhydroxyanisole (BHA), butylhydroxytoluene (BHT), and propyl gallate
- surfactants e.g., polysorbates (TWEEN 20, TWEEN 40, TWEEN 80)
- lipids e.g., dimyristoylphophatidylcholine (DMPC), Dimyristoylphosphatidylglycerol (DMPG), distearoylphophatidylglycerol (DSPG), fillers (e.g., mannitol), organic acids (e.g., citric acid, lactic acid, benzoic acid), hydrophilic polymers (e.g., polyethylene glycols (PEG 300, PEG 400), complexing agents (e.g., niacinamide, nicotinic acid
- These methods comprise administering to the patient a therapeutically effective amount of a preparation prepared from a pharmaceutical formulation of the present invention.
- therapeutically effective amount refers to the amount determined to be required to produce the physiological effect intended and associated with a given drug, as measured according to established pharmacokinetic methods and techniques, for the given administration route. Appropriate and specific therapeutically effective amounts can be readily determined by the attending diagnostician, as one skilled in the art, by the use of conventional techniques.
- the effective dose will vary depending upon a number of factors, including the type and extent of progression of the disease or disorder, the overall health status of the particular patient, the relative biological efficacy of the compound selected, the formulation of the active agent with appropriate excipients, and the route of administration.
- the liquid formulations of bendamustine described herein are intended to be administered via injection, for example, they may be administered subcutaneously, intracutaneously, intravenously, intramuscularly, intra-articularly, intrasynovially, intrasternally, intrathecally, intralesionally, intracranially or via infusion.
- the volume of the liquid formulation of the present invention needed for the required dose can be aseptically withdrawn and transferred to an infusion bag of 0.9% Sodium Chloride (or other pharmaceutically acceptable intravenous solution) for injection. After transfer, the contents of the infusion bag are thoroughly mixed.
- Administration by intravenous infusion is typically provided over a time period of from about 30 to about 60 minutes.
- Previously described lyophilized formulations of bendamustine required reconstitution of the lyophilized bendamustine prior to mixture with the acceptable intravenous solution before infusion.
- the pharmaceutical formulations and preparations of the present invention can be administered in combination with one or more anti-neoplastic agents where the anti-neoplastic agent is given prior to, concurrently with, or subsequent to the administration of the formulation or preparation of the present invention.
- Pharmaceutically acceptable anti-neoplastic agents are known in the art.
- Preferred anti-neoplastic agents are those disclosed in co-pending U.S. application Ser. No. 11/330,868, filed Jan. 12, 2006, the entirety of which is incorporated herein by reference.
- the three replicates were combined and mixed well and then pipetted into amber HPLC vials and placed in stability chambers at 25° C. and 5° C. All the samples were clear and colorless except for the DMI sample which was clear and yellow.
- the 25° C. stability leveled out from about 180 days (about 6 months) to about 365 days (about 12 months, about 1 year). At 5° C., all solutions had a purity greater than 90%.
- the analysis of stability samples can be seen in the graphs of FIGS. 1 and 2 .
- bendamustine (BM1) in 99% propylene glycol degrades significantly when stored at 25° C. for less than 100 days. After storage at 5° C. for about 365 days, the purity of the bendamustine is about 80% or less.
- TREANDA lyophilized mixture of bendamustine hydrochloride and mannitol; 25 mg (bendamustine hydrochloride) vials; 2) a 66% dimethylacetamide (DMA)/34% propylene glycol (PG) (w/w) solution (90 mg (bendamustine hydrochloride)/mL stock); and 3) a 100% DMA solution (45 mg (bendamustine hydrochloride)/mL stock).
- DMA dimethylacetamide
- PG propylene glycol
- the lyophilized powder and stock solutions of bendamustine hydrochloride were constituted or diluted with 0.9% saline, as appropriate, to give solutions of 3 mg bendamustine hydrochloride/ml, just prior to dose administration.
- the resulting solutions were administered as a bolus via a saphenous vein at a fixed volume of 1.0 mL/kg. There was at least a 7-day washout period separating successive doses.
- the aliquoted sample is acidified with 1% formic acid and bendamustine with an added carbon in the carboxylic acid chain is added as an internal standard.
- the samples are evaporated to dryness and the residue is reconstituted with an acetonitrile/water/formic acid/ammonium formate mixture.
- the sample is injected into an HPLC system with LC/MS/MS detection using a Phenomenex Synergi Max-RP column with an acetonitrile/water/formic acid/ammonium formate mobile phase. Pharmacokinetic analyses were performed using noncompartmental methods.
- the 3 formulations were also similar with respect to bendamustine systemic exposure (i.e., Cmax and AUC).
- C max and AUG 0- ⁇ for bendamustine were 6037 ng/mL and 2314 ng•hr/mL for the TREANDA formulation, 7380 ng/mL and 2854 ng•hr/mL for the 66% DMA/34% PG formulation and 6209 ng/mL and 2372 ng•hr/mL for the 100% DMA formulation.
- Plasma clearance (CL) and volume of distribution (V z and V SS ) for bendamustine were also comparable between each of the 3 formulations (See Table III).
- t max , hr is given as Median [range]
- t 1/2 is given as the Harmonic Mean
- ⁇ z is the slope of line in elimination phase used to calculate half-life
- MRT 0-28 is the mean residence time.
- Admixtures in 0.9% sodium chloride 500 mL bag were prepared at a high dose (360 mg bendamustine hydrochloride) and purity was determined over time at room temperature for up to 8 hours using HPLC, using a Zorbax Bonus-RP column with a gradient from 93% 0.1% trifluoroacetic acid in water (Mobile Phase A)/7% 0.1% trifluoroacetic acid in acetonitrile (Mobile Phase B) to 10% Mobile Phase A/90% Mobile Phase B.
- the 66% DMA/34% PG formulation had a concentration of bendamustine hydrochloride of 90 mg/g, so 4 mL was injected into a 500 mL bag of saline, inverted 10 times and sampled at room temperature for 8 hours. After 8 hours the purity was 95.4%. This is within the label requirements for dosing Treanda.
- This formulation of the present invention could be used for up to 8 hours at room temperature.
- reconstituted Treanda can only be stored at room temperature for up to 3 hours.
- the 100% DMA formulation had a concentration of 45 mg/g, so 8 mL was injected into a 500 mL bag of saline, inverted 10 times, and sampled at room temperature for 4 hours. After 4 hours the purity was 97.9%. This formulation of the present invention could be used for more than 4 hours at room temperature.
- the comparative Treanda admixture purity was 95.0% after 4 hours at 25° C.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Stable liquid formulations of bendamustine, and pharmaceutically acceptable salts thereof, and polar aprotic solvents, are described.
Description
- This application is a continuation of U.S. application Ser. No. 16/601,293, filed Oct. 14, 2019, which is a continuation of U.S. application Ser. No. 16/433,510, filed Jun. 6, 2019, which is continuation of U.S. application Ser. No. 16/245,672, filed Jan. 11, 2019, now abandoned, which is a continuation of U.S. application Ser. No. 15/688,182, filed Aug. 28, 2017, which is a continuation of U.S. application Ser. No. 14/814,570, filed Jul. 31, 2015, now abandoned, which is a continuation of U.S. application Ser. No. 14/221,422, filed Mar. 21, 2014, now abandoned, which is a continuation of U.S. application Ser. No. 14/151,242, filed Jan. 9, 2014, now abandoned, which is a continuation of U.S. application Ser. No. 13/655,498, filed Oct. 19, 2012, now abandoned, which is a continuation of U.S. application Ser. No. 13/362,430, filed Jan. 31, 2012, now U.S. Pat. No. 8,344,006, which is a continuation of U.S. application Ser. No. 13/048,325, filed Mar. 15, 2011, now abandoned, which is a continuation of International Application No. PCT/US2009/58023, filed Sep. 23, 2009, which claims the benefit of U.S. Provisional Application No. 61/100,074, filed Sep. 25, 2008, the entireties of which are incorporated by reference herein.
- The present invention relates to liquid formulations of bendamustine, and the pharmaceutical salts thereof.
-
- is an atypical structure with a benzimidazole ring, which structure includes an active nitrogen mustard. Bendamustine was initially synthesized in 1963 in the German Democratic Republic and was available from 1971 to 1992 in that location under the name Cytostasan®. Since that time, it has been marketed in Germany under the tradename Ribomustin®. It is currently available for use in the United States under the tradename Treanda® (Cephalon, Inc., Frazer, Pa.). It has been widely used to treat chronic lymphocytic leukemia, Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, and breast cancer.
- Like other nitrogen mustards, bendamustine hydrolyzes in aqueous solution, with the major degradant being the primary alcohol HP1 (See U.S. application Ser. No. 11/330,868, the entirety of which is incorporated herein):
- In light of its instability in aqueous solution, bendamustine is currently supplied as a lyophilized powder for injection. Just prior to its infusion, the medical practitioner reconstitutes the powder with Sterile Water for Injection. Reconstitution should yield a clear, colorless to pale yellow solution and the powder should completely dissolve in about 5 minutes. If particulate matter is observed, the reconstituted product should not be used and should be discarded. The reconstituted product is then transferred to a 0.9% Sodium Chloride Injection infusion bag within 30 minutes of reconstitution. This admixture should be a clear and colorless to slightly yellow solution. If the admixture comprises particulate matter or is discolored, it should be discarded and a fresh sample prepared.
- The reconstitution of the bendamustine lyophilized powder is time consuming and cumbersome. Moreover, lyophilization of solids on a commercial scale requires specialized equipment and incurs significant expense. As such, formulations of bendamustine that do not require lyophilization and/or reconstitution are needed.
- Solutions of bendamustine hydrochloride in anhydrous propylene glycol, prepared under an inert gas atmosphere, have been reported (GDR Patent 159289). It was reported that analysis of these solutions using thin-layer chromatography, eluting with butanol/acetic acid/water (4:1:5) and detection with Dragendorff reagent and UV (360 nm) did not suggest any decomposition. Curiously, however, commercial development of propylene glycol formulations have heretofore not been reported. Thus, improved liquid formulations of bendamustine are still needed.
- The present invention is directed to liquid pharmaceutical formulations comprising bendamustine, or a pharmaceutically acceptable salt or prodrug thereof, and a polar aprotic solvent. Certain preferred embodiments include liquid pharmaceutical formulations comprising bendamustine, or a pharmaceutically acceptable salt or prodrug thereof, a polar aprotic solvent, and a non-aqueous polar protic solvent. Methods of making and using the formulations of the present invention are also described, as are methods of treating cancer using the claimed formulations.
-
FIG. 1 is a graph of a stability analysis of bendamustine in various solvents at 25° C. -
FIG. 2 is a graph of a stability analysis of bendamustine in various solvents at 5° C. -
FIG. 3 is a graph of bendamustine purity, over time, in 99% propylene glycol, at 5° C. and at 25° C. -
FIG. 4 shows the mean+standard deviation concentration-versus-time profiles of bendamustine in male Cynomolgus monkeys (N=4) administered single 3 mg/kg bolus intravenous doses of bendamustine hydrochloride in 3 different formulations. - Stable, liquid formulations of bendamustine have been discovered and are reported herein.
- Experiments to produce commercially viable propylene glycol preparations have been performed. Unfortunately, the results described in GDR Patent 159289 were not reproducible. Solutions of bendamustine in 99% propylene glycol degraded to non-bendamustine products over a time equivalent to commercial storage. Two of the impurities were identified as propylene glycol esters of bendamustine. As such, a 100% propylene glycol commercial formulation of bendamustine is not feasible for pharmaceutical purposes.
- It has been determined that pharmaceutically acceptable liquid formulations of bendamustine, and the pharmaceutically acceptable salts thereof, in particular the hydrochloride salt, can be prepared by combining bendamustine, or the pharmaceutically acceptable salt thereof, with a polar aprotic solvent or mixture of polar aprotic solvents. Polar, aprotic solvents are known in the art and include, for example, 1-methyl-2-pyrrolidone, 1,3-dimethyl-2-imidazolidinone, dimethylacetamide, dimethyl sulfoxide, acetone, tetrahydrofuran, 1,4-dioxane, acetonitrile, dimethyl formamide, propylene carbonate. See also, e.g., Florence Mottu, et al. Organic solvents for pharmaceutical parenterals and embolic liquids: A review of toxicity data, PDA J. Pharma. Sci. & Tech. vol 54, no.6, 456-469 (Nov.-Dec. 2000). Particularly preferred polar aprotic solvents include dimethylacetamide, dimethyl sulfoxide, and mixtures thereof.
- Without wishing to be held to any particular theory, it is believed that polar, aprotic solvents are sufficiently non-nucleophilic towards bendamustine such that polar aprotic solvent-bendamustine adducts do not form over the course of typical commercial storage conditions. Typical commercial storage conditions include time periods of, for example, about 30 days, about 90 days, about 180 days, and about 365 days (about 1 month, about 3 months, about 6 months, and about 1 year). Typical commercial storage conditions also include temperatures of about 23° C. (ambient room temperature) and refrigerated temperatures below ambient room temperature, for example, about 5° C. Preferably, the liquid formulations of the present invention are stored at refrigerated temperatures.
- It has also been discovered that stable formulations of bendamustine can be obtained by mixing a polar aprotic solvent, or a mixture of polar aprotic solvents, with a non-aqueous polar protic solvent or mixture of nonaqueous polar protic solvents. Pharmaceutically acceptable nonaqueous polar protic solvents are known in the art and include alkyl alcohols, for example, ethanol, ethylene glycol, propylene glycol, butylene glycol, glycerin, polysorbates, for
example TWEEN 20,TWEEN 40, andTWEEN 80, and cyclodextrins (such as hydroxypropyl-(3-cyclodextrin), polyalkylene glycols, such as polyethylene glycol, polypropylene glycol, and polybutylene glycol, and primary amides such as niacinamide. - Such formulations will typically comprise 90% or less, by volume of the formulation, of the nonaqueous polar protic solvent. In other preferred embodiments, formulations will comprise between about 20% and about 85%, by volume of the formulation, of the nonaqueous polar protic solvent. In still other embodiments, formulations will comprise between about 30% and about 70%, by volume of the formulation, of the nonaqueous polar protic solvent. In most preferred embodiments, formulations will comprise about 80%, about 67% or about 34%, by volume of the formulation, of the nonaqueous polar protic solvent.
- Alternatively, formulations of the present invention will comprise 10 moles per liter, or less, of the nonaqueous polar protic solvent. Preferably, formulations of the present invention will comprise between about 4 moles per liter to about 9.5 moles per liter, of the nonaqueous polar protic solvent. In certain embodiments, formulations will comprise about 9.1 moles per liter of the nonaqueous polar protic solvent. In other embodiments, formulations will comprise about 4.6 moles per liter, of the nonaqueous polar protic solvent.
- While not wishing to be held to any particular theory, it is believed that while nonaqueous polar protic solvents are of sufficient nucleophilicity to form potentially undesirable polar protic solvent-bendamustine adducts, such adducts will not form during typical commercial storage if the concentration of the polar protic solvent is kept within the scope of the present invention.
- Liquid formulations of the present invention are stable over the course of a typical commercial storage period. As used herein, “stable” is defined as no more than about a 10% loss of bendamustine under typical commercial storage conditions. Preferably, formulations of the present inventions will have no more than about a 10% loss of bendamustine, more preferably, no more than about a 5% loss of bendamustine, under typical commercial storage conditions.
- Bendamustine converts to non-bendamustine products (i.e., “degrades”) upon exposure to certain nucleophiles, for example, water and alkyene glycols such as propylene glycol. Exposure of bendamustine to water can produce “HP1,” which is undesirable.
- Another undesirable compound that bendamustine can convert to over time is “BM1 dimer.”
- Still another undesirable compound that bendamustine can convert to over time is “DCE.”
- Upon exposure to an alkylene glycol, for example, propylene glycol, esters of bendamustine can form, e.g., PG-1 and PG-2.
- In preferred embodiments of the present invention, analysis of formulations of the present invention will exhibit 1.50% or less of DCE, as determined by HPLC analysis, after about 1 year (about 365 days) at about 5° C. More preferably, the formulations will exhibit 1.0% or less of DCE, as determined by HPLC analysis, after about 1 year (about 365 days) at about 5° C. Even more preferably, the formulations will exhibit 0.5% or less of DCE, as determined by HPLC analysis, after about 1 year (about 365 days) at about 5° C. Most preferably, the formulations will exhibit about 0.1% or less of DCE, as determined by HPLC analysis, after about 1 year (about 365 days) at about 5° C.
- In other embodiments of the present invention, analysis of the formulations will exhibit about 0.4% or less of HP1, as determined by HPLC analysis, after about 1 year (about 365 days) at about 5° C. Preferably, the formulations will exhibit about 0.10% or less of HP1, as determined by HPLC analysis, after about 1 year (about 365 days) at about 5° C.
- In certain other embodiments of the present invention, analysis of the formulations will exhibit about 0.70% or less of BM1 dimer, as determined by HPLC analysis, after about 1 year (about 365 days) at about 5° C. Preferably, the formulations will exhibit about 0.30% or less of dimer, as determined by HPLC analysis, after about 1 year (about 365 days) at about 5° C. In most preferred embodiments, the formulations will exhibit about 0.10% or less of BM1 dimer, as determined by HPLC analysis, after about 1 year (about 365 days) at about 5° C.
- In those embodiments of the present invention comprising alkylene glycol as the nonaqueous polar protic solvent, analysis of those formulations will exhibit 1.5% or less of alkylene glycol esters of bendamustine, as determined by HPLC analysis, after about 1 year (about 365 days) at about 5° C. For example, in those embodiments comprising propylene glycol, analysis of those formulations will exhibit 1.5% or less of propylene glycol esters PG-1 and PG-2, as determined by HPLC analysis, after about 1 year (about 365 days) at about 5° C.
- Analysis of the liquid formulations of the present invention can be performed using techniques known in the art, including, for example, HPLC, gas chromatography, and NMR. After exposure to typical commercial storage conditions, analysis of the formulations of the present invention will indicate that the formulation contains no less than about 90% of the amount of bendamustine present prior to exposure to the storage conditions. Preferably, analysis will indicate that the formulation contains no less than about 95% of the amount of bendamustine present prior to exposure to the storage conditions.
- In preferred embodiments of the present invention, analysis of the formulations of the present invention will indicate that the formulation contains no less than about 90% of the amount of bendamustine present prior to exposure to storage conditions that include temperatures of about 5° C. and time periods of about 30 days (about 1 month) to about 365 days (about 1 year). Preferably, analysis of the formulations of the present invention will indicate that the formulation contains no less than about 90% of the amount of bendamustine present prior to exposure to storage conditions that include temperatures of about 5° C. and time periods of about 30 days (about 1 month), about 90 days (about 3 months), and about 180 days (about 6 months). Preferably, analysis will indicate that the formulation contains no less than about 95% of the amount of bendamustine present prior to exposure to storage conditions that include temperatures of about 5° C. and time periods of about 30 days (about 1 month) to about 365 days (about 1 year). More preferably, analysis will indicate that the formulation contains no less than about 95% of the amount of bendamustine present prior to exposure to storage conditions that include temperatures of about 5° C. and time periods of about 30 days (about 1 month), about 90 days (about 3 months), and about 180 days (about 6 months).
- Formulations of the present invention can comprise pharmaceutically useful concentrations of bendamustine, or a pharmaceutically acceptable salt thereof. Useful concentrations include concentrations ranging from about 5 mg/mL to about 200 mg/mL. Preferably, the concentration of bendamustine, or a pharmaceutically acceptable salt thereof, ranges from about 5 mg/mL to about 120 mg/mL. Preferred concentrations include about 5 mg/mL, about 10 mg/mL, about 20 mg/mL, about 30 mg/mL, about 40 mg/mL, about 50 mg/mL, about 60 mg/mL, about 100 mg/mL and about 200 mg/mL of bendamustine, or a pharmaceutically acceptable salt thereof. Greater than 200 mg/ml of bendamustine, or a pharmaceutically acceptable salt thereof, for example, greater than about 300 mg/mL, are also within the scope of the present invention, as are saturated solutions of bendamustine, or a pharmaceutically acceptable salt thereof.
- As used herein, the term “about” is defined as±10%, preferably±5%,
- In addition to comprising a polar aprotic solvent, or mixture of polar aprotic solvents, and optionally, a nonaqueous polar protic solvent, or mixture of solvents, formulations of the present invention may further comprise other pharmaceutically acceptable excipients. Pharmaceutically acceptable excipients are known in the art and include, for example, antioxidants (e.g., tocopherol (Vitamin E), ascorbic acid, methyl paraben, butylhydroxyanisole (BHA), butylhydroxytoluene (BHT), and propyl gallate), surfactants, (e.g., polysorbates (
TWEEN 20,TWEEN 40, TWEEN 80)), lipids (e.g., dimyristoylphophatidylcholine (DMPC), Dimyristoylphosphatidylglycerol (DMPG), distearoylphophatidylglycerol (DSPG), fillers (e.g., mannitol), organic acids (e.g., citric acid, lactic acid, benzoic acid), hydrophilic polymers (e.g., polyethylene glycols (PEG 300, PEG 400), complexing agents (e.g., niacinamide, nicotinic acid, creatine, cyclodextrins), and preservatives (e.g., benzyl alcohol). - Also within the scope of the invention are methods of treating diseases, such as, for example, chronic lymphocytic leukemia, Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, or breast cancer, with a pharmaceutical formulation of the present invention. These methods comprise administering to the patient a therapeutically effective amount of a preparation prepared from a pharmaceutical formulation of the present invention. The term “therapeutically effective amount,” as used herein, refers to the amount determined to be required to produce the physiological effect intended and associated with a given drug, as measured according to established pharmacokinetic methods and techniques, for the given administration route. Appropriate and specific therapeutically effective amounts can be readily determined by the attending diagnostician, as one skilled in the art, by the use of conventional techniques. The effective dose will vary depending upon a number of factors, including the type and extent of progression of the disease or disorder, the overall health status of the particular patient, the relative biological efficacy of the compound selected, the formulation of the active agent with appropriate excipients, and the route of administration.
- The liquid formulations of bendamustine described herein are intended to be administered via injection, for example, they may be administered subcutaneously, intracutaneously, intravenously, intramuscularly, intra-articularly, intrasynovially, intrasternally, intrathecally, intralesionally, intracranially or via infusion. In a typical preparation, the volume of the liquid formulation of the present invention needed for the required dose can be aseptically withdrawn and transferred to an infusion bag of 0.9% Sodium Chloride (or other pharmaceutically acceptable intravenous solution) for injection. After transfer, the contents of the infusion bag are thoroughly mixed. Administration by intravenous infusion is typically provided over a time period of from about 30 to about 60 minutes. Previously described lyophilized formulations of bendamustine required reconstitution of the lyophilized bendamustine prior to mixture with the acceptable intravenous solution before infusion.
- It is envisioned that the pharmaceutical formulations and preparations of the present invention can be administered in combination with one or more anti-neoplastic agents where the anti-neoplastic agent is given prior to, concurrently with, or subsequent to the administration of the formulation or preparation of the present invention. Pharmaceutically acceptable anti-neoplastic agents are known in the art. Preferred anti-neoplastic agents are those disclosed in co-pending U.S. application Ser. No. 11/330,868, filed Jan. 12, 2006, the entirety of which is incorporated herein by reference.
- Equilibrium solubility was determined for solvents including 1-methyl-2-pyrrolidone (NMP), 1,3-dimethyl-2-imidazolidinone (DMI), dimethylacetamide (DMA), dimethyl sulfoxide (DMSO), acetone, tetrahydrofuran (THF), dimethylformamide (DMF), and propylene carbonate (PC). The solubility of bendamustine hydrochloride was also determined for two solutions, 25 mg/mL niacinamide in DMA and 66% DMA/34% propylene glycol (PG). A saturated solution of bendamustine hydrochloride was made in triplicate for each solvent or solution and mixed on a Lab-Quake with gentle mixing and low shear for 3 days at room temperature. A sample of each suspension was put into a microcentrifuge tube and spun at 10,000 rpm for 5 min on an Eppendorf microcentrifuge. The supernatant was removed and put into a clean vial. Each solution was diluted with sample solvent: 50% NMP/50% 0.1% trifluoroacetic acid in water. A reverse phase method for bendamustine hydrochloride was used to determine the concentration of each sample calculated from a standard. Analysis was performed within 18 hours of preparation of the diluted sample. The solubilities are listed in Table I below. Each value is an average of three samples.
-
TABLE I Assay Sample* % Purity (mg/mL) NMP 99.1 104.0 DMI 98.5 75.8 DMSO 99.5 311.7 DMF 99.6 71.8 66% DMA/34% PG 99.5 110.1 DMA 99.4 56.2 PC 98.7 7.7 Niacinamide/DMA 99.2 61.3 *acetone and THF have no measurable solubility of bendamustine. - The three replicates were combined and mixed well and then pipetted into amber HPLC vials and placed in stability chambers at 25° C. and 5° C. All the samples were clear and colorless except for the DMI sample which was clear and yellow. The 25° C. stability leveled out from about 180 days (about 6 months) to about 365 days (about 12 months, about 1 year). At 5° C., all solutions had a purity greater than 90%. The analysis of stability samples can be seen in the graphs of
FIGS. 1 and 2 . -
TABLE II Impurity profile of certain liquid formulations of Bendamustine HCl after storage at 5° C. for about 12 months BM1 DCE HP1 dimer PG-1 PG-2 Formulation (Area %) (Area %) (Area %) (Area %) (Area %) Niacinamide/DMA 1.40 0.08 0.06 ND ND DMA 1.10 0.08 0.05 ND ND 66% DMA/34% PG 0.12 0.08 0.06 1.09 0.27 DMF 0.07 0.11 0.07 ND ND NMP 0.90 0.10 ND ND ND DMSO 0.04 0.38 0.70 ND ND ND = not detected - Analysis conducted using reverse phase HPLC with 50% NMP/50% 0.1% trifluoroacetic acid in water as the running solvent.
- As can be seen in
FIG. 3 , bendamustine (BM1) in 99% propylene glycol degrades significantly when stored at 25° C. for less than 100 days. After storage at 5° C. for about 365 days, the purity of the bendamustine is about 80% or less. - 4 fasted (18 to 23 hr), drug-naive male cynomolgus monkeys consecutively received single 3-mg/kg bolus intravenous doses of bendamustine hydrochloride prepared from 3 different formulations. The formulations evaluated in the study included: 1) TREANDA (lyophilized mixture of bendamustine hydrochloride and mannitol; 25 mg (bendamustine hydrochloride) vials; 2) a 66% dimethylacetamide (DMA)/34% propylene glycol (PG) (w/w) solution (90 mg (bendamustine hydrochloride)/mL stock); and 3) a 100% DMA solution (45 mg (bendamustine hydrochloride)/mL stock). The lyophilized powder and stock solutions of bendamustine hydrochloride were constituted or diluted with 0.9% saline, as appropriate, to give solutions of 3 mg bendamustine hydrochloride/ml, just prior to dose administration. The resulting solutions were administered as a bolus via a saphenous vein at a fixed volume of 1.0 mL/kg. There was at least a 7-day washout period separating successive doses. During all 3 phases of dosing, blood samples for pharmacokinetic profiling of bendamustine and its 2 active circulating metabolites, γ-hydroxybendamustine (M3) and N-des-methylbendamustine (M4), were collected via a femoral vein immediately prior to dosing and at preselected timepoints through 12 hr postdose. Concentrations of bendamustine, M3 and M4 in plasma samples were determined using a validated high-performance liquid chromatography method with tandem mass spectrometric detection (LC-MS/MS) as follows. Bendamustine and the M3 and M4 metabolites are extracted from plasma by protein precipitation using acetonitrile. After the extraction, the aliquoted sample is acidified with 1% formic acid and bendamustine with an added carbon in the carboxylic acid chain is added as an internal standard. The samples are evaporated to dryness and the residue is reconstituted with an acetonitrile/water/formic acid/ammonium formate mixture. The sample is injected into an HPLC system with LC/MS/MS detection using a Phenomenex Synergi Max-RP column with an acetonitrile/water/formic acid/ammonium formate mobile phase. Pharmacokinetic analyses were performed using noncompartmental methods.
- After single bolus intravenous doses of bendamustine hydrochloride to male cynomolgus monkeys, the shapes of the mean plasma concentration-versus-time profiles of bendamustine were similar in each of the 3 formulations (See
FIG. 4 ). In all cases, the highest observed plasma levels of bendamustine were achieved at 0.083 hr postdose (ie, the first sampling time after dose administration) and subsequent removal of the compound from plasma occurred in a bi-phasic manner that was characterized by an initial rapid distribution phase and a somewhat slower terminal phase of drug elimination. The harmonic mean t112 of the terminal phase was approximately 0.6 hr for each formulation (See Table III). - In addition to the similarities in the shapes of the mean plasma concentration-versus-time profiles, the 3 formulations were also similar with respect to bendamustine systemic exposure (i.e., Cmax and AUC). Specifically, the respective mean values of Cmax and AUG0-∞ for bendamustine were 6037 ng/mL and 2314 ng•hr/mL for the TREANDA formulation, 7380 ng/mL and 2854 ng•hr/mL for the 66% DMA/34% PG formulation and 6209 ng/mL and 2372 ng•hr/mL for the 100% DMA formulation. Plasma clearance (CL) and volume of distribution (Vz and VSS) for bendamustine were also comparable between each of the 3 formulations (See Table III). In Table III, tmax, hr is given as Median [range], t1/2, hr is given as the Harmonic Mean, λz, hr−1 is the slope of line in elimination phase used to calculate half-life, and MRT0-28 is the mean residence time.
- In summary, the pharmacokinetic profiles of bendamustine, M3 and M4 for the 2 liquid formulations of bendamustine hydrochloride were qualitatively and quantitatively similar to those obtained for the TREANDA formulation after single bolus intravenous doses to monkeys.
- Table III shows the mean+/−Standard Deviation pharmacokinetic parameters of bendamustine in male Cynomolgus monkeys (N=4) administered single 3mg/kg bolus intravenous doses of bendamustine hydrochloride in the three different formulations.
-
TABLE III Formulation Parameter TREANDA 66% DMA/34 % PG 100% DMA C0, ng/mL 8664 ± 3841 10716 ± 2033 8956 ± 1965 Cmax, ng/mL 6037 ± 2456 7380 ± 1170 6209 ± 1300 tmax, hr 0.083 0.083 0.083 [0.083 for all] [0.083 for all] [0.083 for all] AUC0-t, ng · hr/mL 2313 ± 800 2853 ± 398 2371 ± 535 AUC0-∞, ng · hr/mL 2314 ± 800 2854 ± 398 2372 ± 535 λz, hr−1 1.220 ± 0.111 1.295 ± 0.108 1.092 ± 0.219 t1/2, hr 0.57 0.54 0.63 CL, L/hr/kg 1.27 ± 0.40 0.96 ± 0.14 1.18 ± 0.27 Vz, L/kg 1.04 ± 0.36 0.74 ± 0.05 1.17 ± 0.44 Vss, L/kg 0.34 ± 0.11 0.26 ± 0.05 0.30 ± 0.04 MRT0-∞, hr 0.26 ± 0.02 0.27 ± 0.02 0.26 ± 0.03 - Admixtures in 0.9% sodium chloride (500 mL bag) were prepared at a high dose (360 mg bendamustine hydrochloride) and purity was determined over time at room temperature for up to 8 hours using HPLC, using a Zorbax Bonus-RP column with a gradient from 93% 0.1% trifluoroacetic acid in water (Mobile Phase A)/7% 0.1% trifluoroacetic acid in acetonitrile (Mobile Phase B) to 10% Mobile Phase A/90% Mobile Phase B.
- The 66% DMA/34% PG formulation had a concentration of bendamustine hydrochloride of 90 mg/g, so 4 mL was injected into a 500 mL bag of saline, inverted 10 times and sampled at room temperature for 8 hours. After 8 hours the purity was 95.4%. This is within the label requirements for dosing Treanda. This formulation of the present invention could be used for up to 8 hours at room temperature. By way of contrast, reconstituted Treanda can only be stored at room temperature for up to 3 hours.
- The 100% DMA formulation had a concentration of 45 mg/g, so 8 mL was injected into a 500 mL bag of saline, inverted 10 times, and sampled at room temperature for 4 hours. After 4 hours the purity was 97.9%. This formulation of the present invention could be used for more than 4 hours at room temperature.
- The comparative Treanda admixture purity was 95.0% after 4 hours at 25° C.
- As those skilled in the art will appreciate, numerous modifications and variations of the present invention are possible in view of the above teachings. It is therefore understood that within the scope of the appended claims, the invention can be practiced otherwise than as specifically described herein, and the scope of the invention is intended to encompass all such variations.
Claims (1)
1. A liquid formulation comprising bendamustine and 1-methyl-2-pyrrolidone (NMP).
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/835,562 US20210008035A1 (en) | 2008-09-25 | 2020-03-31 | Liquid formulations of bendamustine |
US17/015,175 US20210113530A1 (en) | 2008-09-25 | 2020-09-09 | Liquid formulations of bendamustine |
Applications Claiming Priority (13)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10007408P | 2008-09-25 | 2008-09-25 | |
PCT/US2009/058023 WO2010036702A1 (en) | 2008-09-25 | 2009-09-23 | Liquid formulations of bendamustine |
US13/048,325 US20110190363A1 (en) | 2008-09-25 | 2011-03-15 | Liquid formulations of bendamustine |
US13/362,430 US8344006B2 (en) | 2008-09-25 | 2012-01-31 | Liquid formulations of bendamustine |
US13/655,498 US20130041004A1 (en) | 2008-09-25 | 2012-10-19 | Liquid Formulations Of Bendamustine |
US14/151,242 US20140128443A1 (en) | 2008-09-25 | 2014-01-09 | Liquid Formulations Of Bendamustine |
US14/221,422 US20140206733A1 (en) | 2008-09-25 | 2014-03-21 | Liquid Formulations Of Bendamustine |
US14/814,570 US20150335750A1 (en) | 2008-09-25 | 2015-07-31 | Liquid Formulations of Bendamustine |
US15/688,182 US20180125824A1 (en) | 2008-09-25 | 2017-08-28 | Liquid formulations of bendamustine |
US201916245672A | 2019-01-11 | 2019-01-11 | |
US201916433510A | 2019-06-06 | 2019-06-06 | |
US201916601293A | 2019-10-14 | 2019-10-14 | |
US16/835,562 US20210008035A1 (en) | 2008-09-25 | 2020-03-31 | Liquid formulations of bendamustine |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US201916601293A Continuation | 2008-09-25 | 2019-10-14 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/015,175 Continuation US20210113530A1 (en) | 2008-09-25 | 2020-09-09 | Liquid formulations of bendamustine |
Publications (1)
Publication Number | Publication Date |
---|---|
US20210008035A1 true US20210008035A1 (en) | 2021-01-14 |
Family
ID=41559533
Family Applications (10)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/048,325 Abandoned US20110190363A1 (en) | 2008-09-25 | 2011-03-15 | Liquid formulations of bendamustine |
US13/362,430 Active US8344006B2 (en) | 2008-09-25 | 2012-01-31 | Liquid formulations of bendamustine |
US13/655,498 Abandoned US20130041004A1 (en) | 2008-09-25 | 2012-10-19 | Liquid Formulations Of Bendamustine |
US14/084,768 Abandoned US20140080881A1 (en) | 2008-09-25 | 2013-11-20 | Liquid Formulations of Bendamustine |
US14/151,242 Abandoned US20140128443A1 (en) | 2008-09-25 | 2014-01-09 | Liquid Formulations Of Bendamustine |
US14/221,422 Abandoned US20140206733A1 (en) | 2008-09-25 | 2014-03-21 | Liquid Formulations Of Bendamustine |
US14/814,570 Abandoned US20150335750A1 (en) | 2008-09-25 | 2015-07-31 | Liquid Formulations of Bendamustine |
US15/688,182 Abandoned US20180125824A1 (en) | 2008-09-25 | 2017-08-28 | Liquid formulations of bendamustine |
US16/835,562 Abandoned US20210008035A1 (en) | 2008-09-25 | 2020-03-31 | Liquid formulations of bendamustine |
US17/015,175 Abandoned US20210113530A1 (en) | 2008-09-25 | 2020-09-09 | Liquid formulations of bendamustine |
Family Applications Before (8)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/048,325 Abandoned US20110190363A1 (en) | 2008-09-25 | 2011-03-15 | Liquid formulations of bendamustine |
US13/362,430 Active US8344006B2 (en) | 2008-09-25 | 2012-01-31 | Liquid formulations of bendamustine |
US13/655,498 Abandoned US20130041004A1 (en) | 2008-09-25 | 2012-10-19 | Liquid Formulations Of Bendamustine |
US14/084,768 Abandoned US20140080881A1 (en) | 2008-09-25 | 2013-11-20 | Liquid Formulations of Bendamustine |
US14/151,242 Abandoned US20140128443A1 (en) | 2008-09-25 | 2014-01-09 | Liquid Formulations Of Bendamustine |
US14/221,422 Abandoned US20140206733A1 (en) | 2008-09-25 | 2014-03-21 | Liquid Formulations Of Bendamustine |
US14/814,570 Abandoned US20150335750A1 (en) | 2008-09-25 | 2015-07-31 | Liquid Formulations of Bendamustine |
US15/688,182 Abandoned US20180125824A1 (en) | 2008-09-25 | 2017-08-28 | Liquid formulations of bendamustine |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/015,175 Abandoned US20210113530A1 (en) | 2008-09-25 | 2020-09-09 | Liquid formulations of bendamustine |
Country Status (9)
Country | Link |
---|---|
US (10) | US20110190363A1 (en) |
EP (2) | EP2889029A1 (en) |
JP (1) | JP5670335B2 (en) |
CN (2) | CN102164579B (en) |
AU (5) | AU2009296734B2 (en) |
CA (1) | CA2735899A1 (en) |
HK (1) | HK1211462A1 (en) |
MX (1) | MX2011002936A (en) |
WO (1) | WO2010036702A1 (en) |
Families Citing this family (168)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005099724A2 (en) * | 2004-04-13 | 2005-10-27 | Parallel Solutions, Inc. | Functionalized water-soluble polyphosphazene and uses thereof as modifiers of biological agents |
US9012506B2 (en) | 2004-09-28 | 2015-04-21 | Atrium Medical Corporation | Cross-linked fatty acid-based biomaterials |
US9801913B2 (en) | 2004-09-28 | 2017-10-31 | Atrium Medical Corporation | Barrier layer |
US9000040B2 (en) | 2004-09-28 | 2015-04-07 | Atrium Medical Corporation | Cross-linked fatty acid-based biomaterials |
US8436190B2 (en) | 2005-01-14 | 2013-05-07 | Cephalon, Inc. | Bendamustine pharmaceutical compositions |
US11266607B2 (en) * | 2005-08-15 | 2022-03-08 | AbbVie Pharmaceuticals GmbH | Process for the manufacture and use of pancreatin micropellet cores |
US9278161B2 (en) | 2005-09-28 | 2016-03-08 | Atrium Medical Corporation | Tissue-separating fatty acid adhesion barrier |
US9427423B2 (en) | 2009-03-10 | 2016-08-30 | Atrium Medical Corporation | Fatty-acid based particles |
US20070086958A1 (en) * | 2005-10-14 | 2007-04-19 | Medafor, Incorporated | Formation of medically useful gels comprising microporous particles and methods of use |
EP2124522B1 (en) * | 2007-02-05 | 2011-11-16 | National University of Singapore | Putative cytokinin receptor and methods for use thereof |
US8097712B2 (en) | 2007-11-07 | 2012-01-17 | Beelogics Inc. | Compositions for conferring tolerance to viral disease in social insects, and the use thereof |
AR072777A1 (en) | 2008-03-26 | 2010-09-22 | Cephalon Inc | SOLID FORMS OF BENDAMUSTINE CHLORHYDRATE |
CA2735899A1 (en) | 2008-09-25 | 2010-04-01 | Cephalon, Inc. | Liquid formulations of bendamustine |
CA2750462C (en) * | 2009-02-06 | 2014-08-19 | The Procter & Gamble Company | Collapsible water-containing capsules |
MX2011010673A (en) * | 2009-04-10 | 2012-02-21 | Abraxis Bioscience Llc | Nanoparticle formulations and uses therof. |
WO2010129545A2 (en) | 2009-05-04 | 2010-11-11 | Psivida Us, Inc. | Porous silicon drug-eluting particles |
WO2010144675A1 (en) | 2009-06-10 | 2010-12-16 | Plus Chemicals Sa | Polymorphs of bendamustine hcl and processes for preparation thereof |
US20110038910A1 (en) | 2009-08-11 | 2011-02-17 | Atrium Medical Corporation | Anti-infective antimicrobial-containing biomaterials |
US8962584B2 (en) | 2009-10-14 | 2015-02-24 | Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. | Compositions for controlling Varroa mites in bees |
MX344642B (en) * | 2009-12-29 | 2017-01-04 | W R Grace & Co -Conn * | Compositions for forming films having a desired degree of obscuration and methods of making and using the same. |
HUE031208T2 (en) * | 2010-01-28 | 2017-07-28 | Eagle Pharmaceuticals Inc | Formulations of bendamustine |
EP2531168B1 (en) * | 2010-02-04 | 2019-10-30 | ISP Investments LLC | Self adapting polymers for anhydrous sunscreen formulations |
AR080201A1 (en) * | 2010-02-18 | 2012-03-21 | Athenix Corp | DELTA-ENDOTOXINIC GENES OF BACILLUS THURINGIENSIS (AXMI218, AXMI219, AXMI220, AXMI226, AXMI227, AXMI228, AXMI229, AXMI230, AND AXMI231), AND METHODS FOR USE |
CA3049609C (en) * | 2010-02-18 | 2024-02-13 | Athenix Corp. | Axmi221z, axmi222z, axmi223z, axmi224z, and axmi225z delta-endotoxin genes and methods for their use |
WO2011103150A2 (en) * | 2010-02-18 | 2011-08-25 | Cephalon, Inc. | Lyophilized preparations of bendamustine |
CA2790211C (en) | 2010-03-08 | 2020-06-09 | Monsanto Technology Llc | Methods and compositions for delivering polynucleotides into plants |
FR2958155B1 (en) * | 2010-04-02 | 2012-04-20 | Oreal | DECOLORATION COMPOSITION COMPRISING PEROXYGEN SALT IN A HIGHLY RICH BODY BASE |
WO2011137563A1 (en) * | 2010-05-07 | 2011-11-10 | Unilever Plc | High solvent content emulsions |
US8816156B2 (en) * | 2010-06-04 | 2014-08-26 | Monsanto Technology Llc | Transgenic Brassica event MON 88302 and methods of use thereof |
WO2011160170A1 (en) * | 2010-06-21 | 2011-12-29 | Peter Maccallum Cancer Institute | Stimulating immune response |
EP2593141B1 (en) | 2010-07-16 | 2018-07-04 | Atrium Medical Corporation | Composition and methods for altering the rate of hydrolysis of cured oil-based materials |
US8383663B2 (en) | 2010-07-19 | 2013-02-26 | Supratek Pharma Inc. | Bendamustine anionic-catioinic cyclopolysaccharide compositions |
US8802933B2 (en) * | 2010-08-19 | 2014-08-12 | Pioneer Hi Bred International Inc | Bacillus thuringiensis gene with lepidopteran activity |
MX339196B (en) * | 2010-10-28 | 2016-05-16 | Aequus Pharmaceuticals Inc | Aripiprazole compositions and methods for its transdermal delivery. |
US9757374B2 (en) | 2010-10-28 | 2017-09-12 | Aequus Pharmaceuticals Inc. | Aripiprazole compositions and methods for its transdermal delivery |
CN103282020B (en) | 2010-11-01 | 2016-10-26 | 普西维达公司 | Can the silicon-based devices of bioerosion for deliver therapeutic agent |
CA2829400C (en) | 2011-03-10 | 2022-02-15 | Xeris Pharmaceuticals, Inc. | Stable formulations for parenteral injection of peptide drugs |
MX2013014098A (en) * | 2011-06-04 | 2014-10-14 | Texas A & M Univ Sys | Potato transformation compositions, systems, methods, microorganisms, and plants. |
JP2013032332A (en) * | 2011-07-01 | 2013-02-14 | Lintec Corp | Immunoactivator |
WO2013023992A1 (en) * | 2011-08-12 | 2013-02-21 | Bayer Cropscience Nv | Guard cell-specific expression of transgenes in cotton |
EP2755466A4 (en) | 2011-09-13 | 2015-04-15 | Monsanto Technology Llc | Methods and compositions for weed control |
US9840715B1 (en) | 2011-09-13 | 2017-12-12 | Monsanto Technology Llc | Methods and compositions for delaying senescence and improving disease tolerance and yield in plants |
US10829828B2 (en) | 2011-09-13 | 2020-11-10 | Monsanto Technology Llc | Methods and compositions for weed control |
MX361938B (en) | 2011-09-13 | 2018-12-19 | Monsanto Technology Llc | Methods and compositions for weed control. |
US10760086B2 (en) | 2011-09-13 | 2020-09-01 | Monsanto Technology Llc | Methods and compositions for weed control |
MX343072B (en) | 2011-09-13 | 2016-10-21 | Monsanto Technology Llc | Methods and compositions for weed control. |
UY34328A (en) | 2011-09-13 | 2013-04-30 | Monsanto Technology Llc | ? COMPOSITIONS AND METHODS TO CONTROL MALEZAS UNDERSTANDING A POLINUCLEOTIDE AND TRANSFER AGENT, AND THAT MODULATE PROTOPORPHYRINOGEN IX OXIDASE. |
US10806146B2 (en) | 2011-09-13 | 2020-10-20 | Monsanto Technology Llc | Methods and compositions for weed control |
US9920326B1 (en) | 2011-09-14 | 2018-03-20 | Monsanto Technology Llc | Methods and compositions for increasing invertase activity in plants |
DK2758052T3 (en) * | 2011-09-18 | 2018-05-28 | Euro Celtique Sa | Pharmaceutical composition comprising an HDAC inhibitor and a cyclopolysaccharide |
CN104011029B (en) | 2011-09-26 | 2016-06-08 | 费森尤斯卡比肿瘤学有限公司 | A kind ofly prepare improving one's methods of bendamustine hydrochloride |
WO2013052114A1 (en) * | 2011-10-05 | 2013-04-11 | Fmc Corporation | Stabilizer composition of microcrystalline cellulose and carboxymethylcellulose, method for making, and uses |
US9492363B1 (en) * | 2012-01-16 | 2016-11-15 | American Spraytech, L.L.C. | Aerosol sprayable color composition |
US20130210878A1 (en) * | 2012-01-24 | 2013-08-15 | Innopharma, Inc. | Bendamustine compositions and methods therefore |
CA2861324A1 (en) * | 2012-01-27 | 2013-08-01 | Agile Therapeutics, Inc. | Transdermal hormone delivery |
TWI573792B (en) | 2012-02-01 | 2017-03-11 | 歐陸斯迪公司 | Novel therapeutic agents |
US20130210879A1 (en) * | 2012-02-14 | 2013-08-15 | Eagle Pharmaceuticals, Inc. | Formulations of bendamustine |
ES2943668T3 (en) | 2012-03-20 | 2023-06-15 | Eagle Pharmaceuticals Inc | Bendamustine liquid compositions for use in a method of treating conditions responsive to bendamustine in patients requiring reduced volumes for administration |
HUE064884T2 (en) * | 2012-03-20 | 2024-04-28 | Eagle Pharmaceuticals Inc | Formulations of bendamustine |
WO2013148919A1 (en) | 2012-03-30 | 2013-10-03 | The Regents Of The University Of Colorado, A Body Corporate | Treatment of multiple myeloma |
CN104619843B (en) | 2012-05-24 | 2020-03-06 | A.B.种子有限公司 | Compositions and methods for silencing gene expression |
US9125805B2 (en) * | 2012-06-27 | 2015-09-08 | Xeris Pharmaceuticals, Inc. | Stable formulations for parenteral injection of small molecule drugs |
US20230241218A1 (en) * | 2012-07-10 | 2023-08-03 | Eagle Pharmaceuticals, Inc. | Formulations of bendamustine |
DK2879715T3 (en) * | 2012-08-03 | 2023-04-24 | Msm Innovations Inc | METHOD AND KIT FOR BOWEL PREPARATION |
US9951386B2 (en) | 2014-06-26 | 2018-04-24 | 10X Genomics, Inc. | Methods and systems for processing polynucleotides |
EP4397767A3 (en) | 2012-08-14 | 2024-07-31 | 10X Genomics, Inc. | Microcapsule compositions and methods |
US10323279B2 (en) | 2012-08-14 | 2019-06-18 | 10X Genomics, Inc. | Methods and systems for processing polynucleotides |
US10221442B2 (en) | 2012-08-14 | 2019-03-05 | 10X Genomics, Inc. | Compositions and methods for sample processing |
US10752949B2 (en) | 2012-08-14 | 2020-08-25 | 10X Genomics, Inc. | Methods and systems for processing polynucleotides |
US11591637B2 (en) | 2012-08-14 | 2023-02-28 | 10X Genomics, Inc. | Compositions and methods for sample processing |
US9701998B2 (en) | 2012-12-14 | 2017-07-11 | 10X Genomics, Inc. | Methods and systems for processing polynucleotides |
US10400280B2 (en) | 2012-08-14 | 2019-09-03 | 10X Genomics, Inc. | Methods and systems for processing polynucleotides |
US10273541B2 (en) | 2012-08-14 | 2019-04-30 | 10X Genomics, Inc. | Methods and systems for processing polynucleotides |
US9801859B2 (en) | 2012-09-18 | 2017-10-31 | Innopharma Licensing, Llc | Bendamustine formulations |
US9617297B2 (en) * | 2012-10-11 | 2017-04-11 | The Regents Of The University Of California | Apoplast wash fluid recovery for improved recombinant endoglucanase extraction in tabacco leaves |
US10077451B2 (en) | 2012-10-18 | 2018-09-18 | Monsanto Technology Llc | Methods and compositions for plant pest control |
EA029706B1 (en) * | 2012-11-12 | 2018-05-31 | Игнайта, Инк. | Bendamustine alkyl esters and methods of using same |
HUE027287T2 (en) * | 2012-11-19 | 2016-09-28 | Oncotec Pharma Produktion Gmbh | Method for producing a freeze-dried compound |
CA2894694C (en) | 2012-12-14 | 2023-04-25 | 10X Genomics, Inc. | Methods and systems for processing polynucleotides |
US10533221B2 (en) | 2012-12-14 | 2020-01-14 | 10X Genomics, Inc. | Methods and systems for processing polynucleotides |
US9206436B2 (en) * | 2012-12-20 | 2015-12-08 | Ut-Battelle, Llc | Key gene regulating cell wall biosynthesis and recalcitrance in Populus, gene Y |
UA118841C2 (en) | 2013-01-01 | 2019-03-25 | Ей.Бі. СІДС ЛТД. | METHODS OF INTRODUCING dsRNA TO PLANT SEEDS FOR MODULATING GENE EXPRESSION |
US10683505B2 (en) | 2013-01-01 | 2020-06-16 | Monsanto Technology Llc | Methods of introducing dsRNA to plant seeds for modulating gene expression |
US10000767B2 (en) | 2013-01-28 | 2018-06-19 | Monsanto Technology Llc | Methods and compositions for plant pest control |
US9018162B2 (en) | 2013-02-06 | 2015-04-28 | Xeris Pharmaceuticals, Inc. | Methods for rapidly treating severe hypoglycemia |
EP3998342A1 (en) | 2013-02-08 | 2022-05-18 | 10X Genomics, Inc. | Partitioning and processing of analytes and other species |
US8961680B2 (en) * | 2013-03-08 | 2015-02-24 | Tbf Environmental Technology Inc. | Solvent formulations |
US20140271764A1 (en) * | 2013-03-12 | 2014-09-18 | Psivida Us, Inc. | Bioerodible Silicon-Based Delivery Vehicles for Delivery of Therapeutic Agents |
EP2971185A4 (en) | 2013-03-13 | 2017-03-08 | Monsanto Technology LLC | Methods and compositions for weed control |
AU2014248958A1 (en) | 2013-03-13 | 2015-10-01 | Monsanto Technology Llc | Methods and compositions for weed control |
US20140283211A1 (en) | 2013-03-14 | 2014-09-18 | Monsanto Technology Llc | Methods and Compositions for Plant Pest Control |
US10568328B2 (en) | 2013-03-15 | 2020-02-25 | Monsanto Technology Llc | Methods and compositions for weed control |
JP2016512839A (en) | 2013-03-15 | 2016-05-09 | シヴィダ・ユーエス・インコーポレイテッドPsivida Us, Inc. | Biodegradable silicon-based compositions for the delivery of therapeutic substances |
DK2968099T3 (en) * | 2013-03-15 | 2020-07-20 | Maria Beug Deeb Inc Dba T&M Ass | METHODS AND COMPOSITIONS FOR CLEANING AND DISINFECTING SURFACES |
CA2817728A1 (en) * | 2013-05-31 | 2014-11-30 | Pharmascience Inc. | Abuse deterrent immediate release formulation |
EP3030663B1 (en) | 2013-07-19 | 2019-09-04 | Monsanto Technology LLC | Compositions and methods for controlling leptinotarsa |
US9850496B2 (en) | 2013-07-19 | 2017-12-26 | Monsanto Technology Llc | Compositions and methods for controlling Leptinotarsa |
CN103351347A (en) * | 2013-07-29 | 2013-10-16 | 东南大学 | Preparation method of impurity DCE in bendamustine hydrochloride |
ES2957541T3 (en) | 2013-08-27 | 2024-01-22 | Vasilios Voudouris | Pharmaceutical compositions of bendamustine |
HUE059757T2 (en) * | 2013-10-07 | 2023-01-28 | Bristol Myers Squibb Holdings Ireland | Hiv treatment formulation of atazanavir and cobicistat |
WO2015054550A1 (en) * | 2013-10-11 | 2015-04-16 | Luitpold Pharmaceuticals, Inc. | Bendamustine pharmaceutical compositions |
CN105849266A (en) | 2013-11-04 | 2016-08-10 | 孟山都技术公司 | Compositions and methods for controlling arthropod parasite and pest infestations |
UA119253C2 (en) | 2013-12-10 | 2019-05-27 | Біолоджикс, Інк. | Compositions and methods for virus control in varroa mite and bees |
IN2014CH00151A (en) * | 2014-01-13 | 2015-07-17 | Hetero Research Foundation | |
BR112016016337A2 (en) | 2014-01-15 | 2017-10-03 | Monsanto Technology Llc | COMPOSITION AND METHODS FOR CONTROLLING THE GROWTH, DEVELOPMENT OR REPRODUCTION ABILITY OF A PLANT, AND FOR SENSITIZING A PLANT TO AN EPSPS-INHIBITOR HERBICIDIER |
US9320730B2 (en) * | 2014-03-13 | 2016-04-26 | Vasilios Voudouris | Bendamustine solid dispersions and continuous infusion |
US11091770B2 (en) | 2014-04-01 | 2021-08-17 | Monsanto Technology Llc | Compositions and methods for controlling insect pests |
BR112016023625A2 (en) | 2014-04-10 | 2018-06-26 | 10X Genomics, Inc. | fluidic devices, systems and methods for encapsulating and partitioning reagents, and applications thereof |
GB201409485D0 (en) | 2014-05-28 | 2014-07-09 | Euro Celtique Sa | Pharmaceutical composition |
GB201409488D0 (en) | 2014-05-28 | 2014-07-09 | Euro Celtique Sa | Pharmaceutical composition |
GB201409471D0 (en) | 2014-05-28 | 2014-07-09 | Euro Celtique Sa | Pharmaceutical composition |
EP3158067B1 (en) | 2014-06-23 | 2020-08-12 | Monsanto Technology LLC | Compositions and methods for regulating gene expression via rna interference |
EP3161138A4 (en) | 2014-06-25 | 2017-12-06 | Monsanto Technology LLC | Methods and compositions for delivering nucleic acids to plant cells and regulating gene expression |
WO2015200893A2 (en) | 2014-06-26 | 2015-12-30 | 10X Genomics, Inc. | Methods of analyzing nucleic acids from individual cells or cell populations |
EP3167049A4 (en) | 2014-07-08 | 2017-11-29 | MIMEDX Group Inc. | Micronized wharton's jelly |
US20160022604A1 (en) * | 2014-07-23 | 2016-01-28 | Cadila Healthcare Limited | Directly compressed ospemifene compositions |
US10378012B2 (en) | 2014-07-29 | 2019-08-13 | Monsanto Technology Llc | Compositions and methods for controlling insect pests |
EP3871709A1 (en) | 2014-08-06 | 2021-09-01 | Xeris Pharmaceuticals, Inc. | Syringes, kits, and methods for intracutaneous and/or subcutaneous injection of pastes |
HUE053962T2 (en) * | 2014-09-11 | 2021-08-30 | Gelita Ag | Gelatin/pectin particles |
JP6943761B2 (en) * | 2014-09-17 | 2021-10-06 | ロンザ,エルエルシー | Activated hydrogen peroxide disinfectant composition |
AU2015339148B2 (en) | 2014-10-29 | 2022-03-10 | 10X Genomics, Inc. | Methods and compositions for targeted nucleic acid sequencing |
US9975122B2 (en) | 2014-11-05 | 2018-05-22 | 10X Genomics, Inc. | Instrument systems for integrated sample processing |
US9603930B2 (en) * | 2014-12-04 | 2017-03-28 | Navinta, Llc | Liquid bendamustine formulation |
WO2016111285A1 (en) * | 2015-01-06 | 2016-07-14 | 山田 修 | Medicinal composition, blood treatment device, cosmetic, food and drink using combustion synthesis material |
KR102321863B1 (en) | 2015-01-12 | 2021-11-08 | 10엑스 제노믹스, 인크. | Method and system for preparing nucleic acid sequencing library and library prepared using same |
EP3256589B1 (en) | 2015-01-22 | 2021-12-22 | Monsanto Technology LLC | Compositions and methods for controlling leptinotarsa |
AU2016222719B2 (en) | 2015-02-24 | 2022-03-31 | 10X Genomics, Inc. | Methods for targeted nucleic acid sequence coverage |
EP4286516A3 (en) | 2015-02-24 | 2024-03-06 | 10X Genomics, Inc. | Partition processing methods and systems |
EP3262233A1 (en) | 2015-02-25 | 2018-01-03 | The Procter and Gamble Company | Fibrous structures comprising a surface softening composition |
US20160303043A1 (en) * | 2015-04-16 | 2016-10-20 | Kate Somerville Skincare, LLC | Self-foaming compositions and methods |
CN107750125A (en) | 2015-06-02 | 2018-03-02 | 孟山都技术有限公司 | For by the composition and method in delivery of polynucleotides to plant |
AU2016270913A1 (en) | 2015-06-03 | 2018-01-04 | Monsanto Technology Llc | Methods and compositions for introducing nucleic acids into plants |
US9649364B2 (en) | 2015-09-25 | 2017-05-16 | Xeris Pharmaceuticals, Inc. | Methods for producing stable therapeutic formulations in aprotic polar solvents |
PL3320143T3 (en) | 2015-07-10 | 2020-05-18 | The Procter & Gamble Company | Fabric care composition comprising metathesized unsaturated polyol esters |
US11590205B2 (en) | 2015-09-25 | 2023-02-28 | Xeris Pharmaceuticals, Inc. | Methods for producing stable therapeutic glucagon formulations in aprotic polar solvents |
DK3882357T3 (en) | 2015-12-04 | 2022-08-29 | 10X Genomics Inc | Methods and compositions for the analysis of nucleic acids |
CN110772480B (en) * | 2016-03-25 | 2022-05-17 | 南京百劲企业管理咨询有限公司 | Bendamustine medicament composition and application thereof |
WO2017197338A1 (en) | 2016-05-13 | 2017-11-16 | 10X Genomics, Inc. | Microfluidic systems and methods of use |
US10821061B2 (en) * | 2016-07-08 | 2020-11-03 | The Gillette Company Llc | Liquid compositions for hair removal devices comprising metathesized unsaturated polyol esters |
US10905677B2 (en) * | 2016-08-31 | 2021-02-02 | Navinta, Llc | Bendamustine solution formulations |
US11826466B2 (en) | 2016-08-31 | 2023-11-28 | Navinta, Llc | Bendamustine solution formulations |
US11266631B2 (en) | 2016-10-11 | 2022-03-08 | Purdue Pharmaceutical Products L.P. | Hodgkin lymphoma therapy |
DE102016223333A1 (en) * | 2016-11-24 | 2018-05-24 | Henkel Ag & Co. Kgaa | Alkaline hair whitening agents containing oxidizing agents and specific carboxylic esters as keratin crosslinkers |
US10011872B1 (en) | 2016-12-22 | 2018-07-03 | 10X Genomics, Inc. | Methods and systems for processing polynucleotides |
US10815525B2 (en) | 2016-12-22 | 2020-10-27 | 10X Genomics, Inc. | Methods and systems for processing polynucleotides |
US10550429B2 (en) | 2016-12-22 | 2020-02-04 | 10X Genomics, Inc. | Methods and systems for processing polynucleotides |
EP4029939B1 (en) | 2017-01-30 | 2023-06-28 | 10X Genomics, Inc. | Methods and systems for droplet-based single cell barcoding |
KR20220119169A (en) * | 2017-03-01 | 2022-08-26 | 아레나 파마슈티칼스, 인크. | Compositions comprising pgi2-receptor agonists and processes for the preparation thereof |
US10398670B2 (en) * | 2017-04-24 | 2019-09-03 | Knoze Jr. Corporation | Oral microbiota promotion for oral and/or sinus infections |
US20180340169A1 (en) | 2017-05-26 | 2018-11-29 | 10X Genomics, Inc. | Single cell analysis of transposase accessible chromatin |
SG11201901822QA (en) | 2017-05-26 | 2019-03-28 | 10X Genomics Inc | Single cell analysis of transposase accessible chromatin |
AU2018275686B2 (en) | 2017-06-02 | 2024-02-01 | Xeris Pharmaceuticals, Inc. | Precipitation resistant small molecule drug formulations |
GB201709402D0 (en) | 2017-06-13 | 2017-07-26 | Euro Celtique Sa | Compounds for treating t-pll |
GB201709403D0 (en) | 2017-06-13 | 2017-07-26 | Euro Celtique Sa | Compounds for treating sarcoma |
GB201709406D0 (en) | 2017-06-13 | 2017-07-26 | Euro-Cletique S A | Compounds for treating TNBC |
GB201709405D0 (en) | 2017-06-13 | 2017-07-26 | Euro Celtique Sa | Compounds for treating ovarian cancer |
US10471033B2 (en) * | 2017-09-15 | 2019-11-12 | Knoze Jr. Corporation | Oral microbiota promotion for immune system associated inflammations |
BR112020006360A2 (en) * | 2017-10-05 | 2020-09-24 | Tube Pharmaceuticals Gmbh | composition for use as a medicament and oral pharmaceutical composition comprising bendamustine or a pharmaceutically acceptable salt or solvate, use and method of delivery of bendamustine or a pharmaceutically acceptable salt or solvate, method of treating a disease or dysfunction in a subject in need of same |
WO2019097413A1 (en) * | 2017-11-15 | 2019-05-23 | Intas Pharmaceuticals Ltd. | Stable non-aqueous pharmaceutical compositions |
SG11201913654QA (en) | 2017-11-15 | 2020-01-30 | 10X Genomics Inc | Functionalized gel beads |
US10829815B2 (en) | 2017-11-17 | 2020-11-10 | 10X Genomics, Inc. | Methods and systems for associating physical and genetic properties of biological particles |
US11752135B2 (en) | 2018-03-29 | 2023-09-12 | Project Pharmaceutics Gmbh | Liquid pharmaceutical formulation |
SG11202009889VA (en) | 2018-04-06 | 2020-11-27 | 10X Genomics Inc | Systems and methods for quality control in single cell processing |
JP2021534253A (en) * | 2018-08-17 | 2021-12-09 | ホスピーラ オーストラリア ピーティーワイ リミテッド | Liquid bendamustine pharmaceutical composition |
US11730815B2 (en) | 2018-11-26 | 2023-08-22 | Good Health, Llc | Stable liquid pharmaceutical compositions comprising bendamustine |
JP7235288B2 (en) * | 2019-01-07 | 2023-03-08 | コーアイセイ株式会社 | Liquid formulations of bendamustine |
CN110123747A (en) * | 2019-04-26 | 2019-08-16 | 嘉兴市爵拓科技有限公司 | The preparation of bendamustine |
US11707450B1 (en) * | 2022-03-03 | 2023-07-25 | Slayback Pharma Llc | Stable pharmaceutical compositions of bendamustine |
Family Cites Families (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE159289C (en) | 1903-10-08 | 1905-03-16 | ||
DD159289A1 (en) * | 1981-06-01 | 1983-03-02 | Uwe Olthoff | METHOD FOR PRODUCING STABLE INJECTION SOLUTIONS OF N-LOST COMPOUNDS |
DD159877A1 (en) | 1981-06-12 | 1983-04-13 | Wolfgang Krueger | PROCESS FOR PREPARING 4- [1-METHYL-5-BIS (2-CHLOROETHYL) AMINO-BENZIMIDAZOLYL-2] BUTTERIC ACID |
IT1153974B (en) * | 1982-09-23 | 1987-01-21 | Erba Farmitalia | PHARMACOLOGICAL COMPOSITIONS BASED ON CISPLATIN AND METHOD FOR THEIR OBTAINMENT |
DE3446873A1 (en) * | 1984-12-21 | 1986-07-10 | Merckle Gmbh | LIQUID DICLOFENAC PREPARATIONS |
US5204335A (en) * | 1986-10-31 | 1993-04-20 | Asta Pharma Aktiengesellschaft | Ifosfamide lyophilisate and process for its preparation |
US5051257A (en) * | 1989-05-09 | 1991-09-24 | Pietronigro Dennis D | Antineoplastic solution and method for treating neoplasms |
US5162115A (en) * | 1989-05-09 | 1992-11-10 | Pietronigro Dennis D | Antineoplastic solution and method for treating neoplasms |
DD293808A5 (en) | 1990-04-23 | 1991-09-12 | Zi Fuer Mikrobiologie Uns Experimentelle Therapie,De | PROCESS FOR PREPARING (5- [BIS- (2-CHLOROETHYL) AMINO] -1-METHYL-BENZIMIDAZOLYL (2) ETHANEAN ACORESIS |
US5227373A (en) * | 1991-10-23 | 1993-07-13 | Bristol-Myers Squibb Co. | Lyophilized ifosfamide compositions |
DK0669836T3 (en) * | 1992-11-13 | 1996-10-14 | Idec Pharma Corp | Therapeutic use of chimeric and radiolabeled antibodies and human B lymphocyte restricted differentiation antigen for the treatment of B cell lymphoma |
US5595721A (en) * | 1993-09-16 | 1997-01-21 | Coulter Pharmaceutical, Inc. | Radioimmunotherapy of lymphoma using anti-CD20 |
EP0725642B1 (en) * | 1993-10-27 | 1999-12-01 | PHARMACIA & UPJOHN COMPANY | Stabilized prostaglandin e 1 |
US5561121A (en) | 1993-11-09 | 1996-10-01 | American Cyanamid Company | Stable lyophilized thiotepa composition |
US5955504A (en) | 1995-03-13 | 1999-09-21 | Loma Linda University Medical Center | Colorectal chemoprotective composition and method of preventing colorectal cancer |
DE19529057B4 (en) * | 1995-08-08 | 2007-12-13 | Baxter Healthcare S.A. | Ifosfamide lyophilizate preparations |
US6261537B1 (en) * | 1996-10-28 | 2001-07-17 | Nycomed Imaging As | Diagnostic/therapeutic agents having microbubbles coupled to one or more vectors |
US6077850A (en) * | 1997-04-21 | 2000-06-20 | G.D. Searle & Co. | Substituted benzopyran analogs for the treatment of inflammation |
US6034256A (en) * | 1997-04-21 | 2000-03-07 | G.D. Searle & Co. | Substituted benzopyran derivatives for the treatment of inflammation |
US20040072889A1 (en) * | 1997-04-21 | 2004-04-15 | Pharmacia Corporation | Method of using a COX-2 inhibitor and an alkylating-type antineoplastic agent as a combination therapy in the treatment of neoplasia |
WO2000002555A1 (en) * | 1998-07-09 | 2000-01-20 | Nardella Francis A | Methods and compositions for the treatment of chronic lymphocytic leukemia |
US5972912A (en) * | 1998-12-17 | 1999-10-26 | S.P. Pharmaceuticals | Method for lyophilizing ifosfamide |
US6569402B1 (en) * | 1998-12-18 | 2003-05-27 | Bristol-Myers Squibb Pharma Company | Vitronectin receptor antagonist pharmaceuticals |
US6380210B1 (en) * | 1999-04-02 | 2002-04-30 | Neurogen Corporation | Heteroaryl fused aminoalkyl-imidazole derivatives: selective modulators of GABAa receptors |
US6545034B1 (en) * | 1999-07-23 | 2003-04-08 | The Regents Of The University Of California | Use of etodolac for the treatment of chronic lymphocytic leukemia |
DE10016077A1 (en) | 2000-03-31 | 2001-12-13 | Cellcontrol Biomedical Lab Gmb | Automated testing of activity of cell-modifying agents useful for selecting cytostatic agents for particular treatments |
US20040152672A1 (en) * | 2000-08-09 | 2004-08-05 | Carson Dennis A. | Indole compounds useful for the treatment of cancer |
KR20040025881A (en) * | 2000-12-11 | 2004-03-26 | 다케다 야쿠힌 고교 가부시키가이샤 | Medicinal compositions having improved absorbability |
US20040058956A1 (en) * | 2000-12-11 | 2004-03-25 | Yohko Akiyama | Pharmaceutical composition having an improved water solubility |
US8679520B2 (en) * | 2001-10-15 | 2014-03-25 | Hemoteq Ag | Coating of stents for preventing restenosis |
US6613927B1 (en) * | 2002-02-08 | 2003-09-02 | American Pharmaceutical Partners, Inc. | Sterile lyophilized ifosfamide and associated methods |
DE10306724A1 (en) | 2002-02-28 | 2003-09-18 | G O T Therapeutics Gmbh | Liposomes, useful in compositions for the treatment of malignant diseases, especially non-Hodgkin lymphoma and chronic lymphatic leukemia, comprise a high bendamustine content, |
DE60319681T2 (en) | 2002-03-22 | 2009-03-12 | Ludwig Maximilian Universität | ZYTOKAPAZITÄT PROCESS |
EP1354952A1 (en) | 2002-04-17 | 2003-10-22 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Smac-peptides as therapeutics against cancer and autoimmune diseases |
EP1495124A2 (en) | 2002-04-17 | 2005-01-12 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Smac-peptides as therapeutics against cancer and autoimmune diseases |
DE50305580D1 (en) * | 2002-05-09 | 2006-12-14 | Hemoteq Gmbh | COMPOUNDS AND METHOD FOR THE HEMOCOMPATIBLE COATING OF SURFACES |
AU2003258061A1 (en) * | 2002-08-02 | 2004-02-23 | Salmedix, Inc. | Therapeutic inhibitionof protein kinases in cancer cells |
DE10304403A1 (en) * | 2003-01-28 | 2004-08-05 | Röhm GmbH & Co. KG | Process for the preparation of an oral dosage form with immediate disintegration and drug release |
EP1444989A1 (en) | 2003-02-07 | 2004-08-11 | Giorgio Dr. Stassi | Sensitizing cells for apoptosis by selectively blocking cytokines |
CA2516191A1 (en) * | 2003-02-14 | 2004-09-02 | Salmedix, Inc | Compositions and methods for the detection and treatment of methylthioadenosine phosphorylase deficient cancers |
CN1829514A (en) * | 2003-07-25 | 2006-09-06 | 惠氏公司 | CCI-779 lyophilized formulations |
EP1814544A4 (en) * | 2004-11-05 | 2009-12-02 | Cephalon Inc | Cancer treatments |
CN101119708B (en) * | 2005-01-14 | 2014-12-24 | 赛福伦公司 | Bendamustine pharmaceutical compositions |
US8436190B2 (en) * | 2005-01-14 | 2013-05-07 | Cephalon, Inc. | Bendamustine pharmaceutical compositions |
US7872050B2 (en) * | 2005-03-14 | 2011-01-18 | Yaupon Therapeutics Inc. | Stabilized compositions of volatile alkylating agents and methods of using thereof |
AR072777A1 (en) * | 2008-03-26 | 2010-09-22 | Cephalon Inc | SOLID FORMS OF BENDAMUSTINE CHLORHYDRATE |
CA2735899A1 (en) | 2008-09-25 | 2010-04-01 | Cephalon, Inc. | Liquid formulations of bendamustine |
-
2009
- 2009-09-23 CA CA2735899A patent/CA2735899A1/en not_active Abandoned
- 2009-09-23 AU AU2009296734A patent/AU2009296734B2/en active Active
- 2009-09-23 MX MX2011002936A patent/MX2011002936A/en active IP Right Grant
- 2009-09-23 CN CN200980137977.5A patent/CN102164579B/en active Active
- 2009-09-23 WO PCT/US2009/058023 patent/WO2010036702A1/en active Application Filing
- 2009-09-23 JP JP2011529180A patent/JP5670335B2/en active Active
- 2009-09-23 EP EP15152744.7A patent/EP2889029A1/en not_active Withdrawn
- 2009-09-23 EP EP09740213A patent/EP2326306A1/en not_active Withdrawn
- 2009-09-23 CN CN201410449785.0A patent/CN104224703A/en active Pending
-
2011
- 2011-03-15 US US13/048,325 patent/US20110190363A1/en not_active Abandoned
- 2011-12-01 HK HK15111733.2A patent/HK1211462A1/en unknown
-
2012
- 2012-01-31 US US13/362,430 patent/US8344006B2/en active Active
- 2012-10-19 US US13/655,498 patent/US20130041004A1/en not_active Abandoned
-
2013
- 2013-11-20 US US14/084,768 patent/US20140080881A1/en not_active Abandoned
-
2014
- 2014-01-09 US US14/151,242 patent/US20140128443A1/en not_active Abandoned
- 2014-03-21 US US14/221,422 patent/US20140206733A1/en not_active Abandoned
-
2015
- 2015-07-31 US US14/814,570 patent/US20150335750A1/en not_active Abandoned
- 2015-07-31 AU AU2015207940A patent/AU2015207940B2/en active Active
-
2016
- 2016-05-18 AU AU2016203246A patent/AU2016203246B2/en active Active
- 2016-10-19 AU AU2016247123A patent/AU2016247123A1/en not_active Abandoned
-
2017
- 2017-08-28 US US15/688,182 patent/US20180125824A1/en not_active Abandoned
-
2018
- 2018-03-23 AU AU2018202107A patent/AU2018202107A1/en not_active Abandoned
-
2020
- 2020-03-31 US US16/835,562 patent/US20210008035A1/en not_active Abandoned
- 2020-09-09 US US17/015,175 patent/US20210113530A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AU2016247123A1 (en) | 2016-11-03 |
CA2735899A1 (en) | 2010-04-01 |
US20210113530A1 (en) | 2021-04-22 |
EP2326306A1 (en) | 2011-06-01 |
AU2015207940A1 (en) | 2015-08-20 |
US20180125824A1 (en) | 2018-05-10 |
US20140206733A1 (en) | 2014-07-24 |
JP2012503666A (en) | 2012-02-09 |
AU2018202107A1 (en) | 2018-04-19 |
AU2009296734B2 (en) | 2016-02-18 |
US20150335750A1 (en) | 2015-11-26 |
AU2009296734A1 (en) | 2010-04-01 |
WO2010036702A1 (en) | 2010-04-01 |
CN102164579A (en) | 2011-08-24 |
US8344006B2 (en) | 2013-01-01 |
HK1211462A1 (en) | 2016-05-27 |
US20130041004A1 (en) | 2013-02-14 |
AU2015207940B2 (en) | 2016-11-10 |
US20110190363A1 (en) | 2011-08-04 |
CN102164579B (en) | 2014-10-15 |
JP5670335B2 (en) | 2015-02-18 |
MX2011002936A (en) | 2011-04-11 |
EP2889029A1 (en) | 2015-07-01 |
US20140080881A1 (en) | 2014-03-20 |
US20140128443A1 (en) | 2014-05-08 |
CN104224703A (en) | 2014-12-24 |
AU2016203246B2 (en) | 2017-09-21 |
US20120129904A1 (en) | 2012-05-24 |
AU2016203246A1 (en) | 2016-06-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20210008035A1 (en) | Liquid formulations of bendamustine | |
US9572888B2 (en) | Formulations of bendamustine | |
AU2017318591B2 (en) | Bendamustine solution formulations | |
US9603930B2 (en) | Liquid bendamustine formulation | |
WO2017175098A1 (en) | Stable liquid pharmaceutical formulations of bendamustine | |
WO2016005995A2 (en) | Glycol free stable liquid compositions of bendamustine | |
US20150087681A1 (en) | Bendamustine HCL Stable Lyophilized Formulations | |
US11826466B2 (en) | Bendamustine solution formulations | |
WO2014170769A2 (en) | Bendamustine lyophilized pharmaceutical compositions | |
US20140275122A1 (en) | Voriconazole Formulations | |
US20190275102A1 (en) | Sterile injectable composition comprising carfilzomib |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: APPLICATION DISPATCHED FROM PREEXAM, NOT YET DOCKETED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |